Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

November 10, 2017: By Jon Swedien


Tear Film Completes $9 Series A Round

Tear Film Innovations announced Nov. 7 it completed a $9 million Series A preferred stock funding round.

The San Diego company’s flagship product, the iLux system, is an investigational device for dry eye and is under US FDA review.

The device enables eye care professionals to provide in-office treatment of blocked meibomian glands through targeted heating and compression of affected eyelids. TFI recently completed a multi-site clinical study to demonstrate the safety and efficacy of the system.

Visionary Ventures Fund and Tigris Ventures led the financing round.

exicure-logoExicure Raises $31.4 Million in Private Financing

Exicure has raised about $31.4 million in private financing, the company announced Nov. 6.

The Skokie, Illinois, company is focused on creating drug treatments using three-dimensional spherical nucleic acid constructs. Exicure is pursuing an ophthalmic target candidate but has not disclosed the indication it is seeking. The ophthalmic target candidate would be delivered to the retina via an eye drop.

Exicure is also pursuing chronic conditions and orphan diseases in dermatology, respiratory and gastric disorders, and solid tumors.

In the initial private placement announced in September, Exicure raised approximately $20.1 million. Exicure raised more than $11.2 million in a subsequent financing, for a total of about $31.4 million.

download (2)Genisphere Completes $7 Million Capital Raise

Genisphere has completed a $7 million capital raise, the Hatfield, Pennsylvania, company announced Nov. 1

Genisphere is advancing its 3DNA nanotechnology platform for targeted drug delivery, and its product pipeline includes GL-249, a proposed preventive treatment for posterior capsule opacification (PCO).

PCO is a vision impairing disease that occurs in some adults and in most children following cataract surgery. PCO arises when myofibroblast cells grow in the capsule surrounding the surgical site and form cloudy scar tissue inside the eye that blocks vision. While PCO is treated readily by laser therapy, the procedure is neither risk free nor available in the developing world, Genisphere said.

Genisphere said the money it raised will be used to advance its 3DNA nanotechnology and to serve other corporate purposes.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023